Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Neoplasm Metastasis × ridaforolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 2 Solid Tumors 1 Recurrence 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Lymphoma 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Advanced Cancers 1

Interventions

Gemcitabine 36 pembrolizumab 28 Paclitaxel 28 Nivolumab 28 Capecitabine 28 Bevacizumab 27 Fluorouracil 26 Oxaliplatin 25 Docetaxel 25 Leucovorin 22 Cyclophosphamide 22 Cisplatin 22 aldesleukin 19 Radiosurgery 17 Carboplatin 17 Interleukin-2 16 fludarabine phosphate 15 fludarabine 15 Irinotecan 15 Cetuximab 14 Trastuzumab 13 Prednisone 13 Ipilimumab 13 Pemetrexed 12 Fulvestrant 12 Everolimus 12 Panitumumab 11 Magnetic Resonance Spectroscopy 11 130-nm albumin-bound paclitaxel 10 aflibercept 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00874731 2019-05-06

MK-8669-037

Merck Sharp & Dohme LLC

Phase 1 Completed

23 enrolled 14 charts

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡